Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection
Annals of Pharmacotherapy · 29.10.2026
DOI: 10.1177/10600280261496876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 29.10.2026. Verfasst von Elias B Chahine und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Administration, Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, FL, USA. Die Arbeit nennt 68 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection. Data Sources: A literature search was conducted in PubMed and Google Scholar (January 2016-August 2026) using the search terms bictegravir and lenacapavir . Other data sources included abstracts presented at recent conferences and the prescribing information. Study Selection and Data Extraction: All English-language studies assessing the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection were considered for inclusion. Data Synthesis: Bictegravir is an established second-generation integrase strand transfer inhibitor (INSTI), whereas lenacapavir is a novel capsid inhibitor. Both antiretrovirals are highly active against HIV-1. Bictegravir/lenacapavir 75 mg/50 mg was shown to be safe and effective in two phase 3 clinical trials after switching from complex antiretroviral therapy (ART) or bictegravir/emtricitabine/tenofovir alafenamide. The Food and Drug Administration approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable ART with no resistance to the individual components. It is available as a single-tablet regimen (STR) taken orally once daily. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Bictegravir/lenacapvir is the first INSTI-capsid inhibitor 2-drug STR indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and/or those who cannot use a nucleos(t)ide or a non-nucleoside reverse transcriptase inhibitor. It is not active against hepatitis B virus coinfection.
Conclusions
Bictegravir/lenacapvir is safe and efficacious as a 2-drug regimen for the treatment of adults with HIV-1 infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Administration, Palm Beach Atlantic University Gregory School of Pharmacy, West Palm Beach, FL, USA.
- HIV Medicine, Department of Pharmacy, Albany Med Health System, NY, USA.
- Department of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, USA.
- Department of Pharmacy Practice, Nova Southeastern University Silverman College of Pharmacy, Fort Lauderdale, FL, USA.
ORCID-Profile: Elias B Chahine, John J Faragon, Nimish Patel, Elizabeth M Sherman
Zitieren
APA
Chahine, E. B., Faragon, J. J., Patel, N., & Sherman, E. M. (2026). Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261496876
Vancouver
Chahine EB, Faragon JJ, Patel N, Sherman EM. Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261496876
BibTeX
@article{Chahine2026,
author = {Chahine, Elias B and Faragon, John J and Patel, Nimish and Sherman, Elizabeth M},
title = {Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261496876}
}
EUVIMED